Artiva Biotherapeutics Spotlights RA as Lead NK Cell Program, Eyes H1 Efficacy Data Catalyst at Needham

Artiva Biotherapeutics (NASDAQ: ARTV) is prioritizing rheumatoid arthritis (RA) as the lead indication for its non-genetically modified natural killer (NK) cell therapy platform, executives said during a discussion at the Needham Healthcare Conference. Speaking with Needham Senior Biotech Analyst Gil Blum, CEO Fred Aslan outlined the company's mechanism of action, the upcoming clinical data catalyst in